Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in antitumor vaccines.

S L Hu, I Hellström, K E Hellström

    Biotechnology (Reading, Mass.)
    |January 1, 1992
    PubMed
    Summary

    Immunization with anti-idiotypic antibodies (Ab2) shows potential for cancer immunotherapy by stimulating antitumor immunity. Further research is needed to optimize Ab2-based therapies for effective tumor destruction in humans.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Patients' expectations and experiences of being involved in their own care in the emergency department: A qualitative interview study.

    Journal of clinical nursing·2021
    Same author

    Living Unnoticed: Cognitive Impairment in Older People with Multimorbidity.

    The journal of nutrition, health & aging·2016
    Same author

    To adjust and endure: a qualitative study of symptom burden in older people with multimorbidity.

    Applied nursing research : ANR·2015
    Same author

    'Are decisions about discharge of elderly hospital patients mainly about freeing blocked beds?' A qualitative observational study.

    BMJ open·2012
    Same author

    Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

    Gynecologic oncology·2004
    Same author

    What constitutes good care for people with dementia?

    British journal of nursing (Mark Allen Publishing)·2002

    Area of Science:

    • Immunology
    • Oncology
    • Cancer Research

    Background:

    • Anti-idiotypic antibodies (Ab2) can elicit antitumor immune responses in preclinical models.
    • The precise role of Ab2 in tumor immunity, including potential tumor growth enhancement, requires further investigation.
    • Evidence suggests Ab2 may offer therapeutic benefits in human cancer patients.

    Purpose of the Study:

    • To explore the potential of anti-idiotypic antibodies (Ab2) in inducing antitumor immunity.
    • To understand the mechanisms by which Ab2 might lead to tumor destruction.
    • To evaluate the therapeutic implications of Ab2 responses in cancer patients.

    Main Methods:

    • Preclinical studies involving immunization with anti-idiotypic antibodies in animal models.
    • Analysis of immune responses, including cell-mediated and humoral immunity.
    • Review of clinical evidence and patient responses to Ab2 therapy.

    Main Results:

    • Immunization with Ab2 induced antitumor immunity in animal models, sometimes leading to tumor destruction.
    • Ab2 presence has occasionally been linked to enhanced tumor growth, necessitating careful study.
    • Some human cancer patients receiving Ab2 showed therapeutic benefit, with a vigorous Ab2 response correlating with better clinical outcomes.

    Conclusions:

    • Anti-idiotypic antibodies (Ab2) hold promise for cancer immunotherapy by stimulating antitumor immune responses.
    • Optimizing Ab2-based strategies is crucial to ensure tumor destruction rather than enhancement.
    • While clinical data are limited, the potential for Ab2 to mediate human cancer destruction warrants continued research.

    Related Experiment Videos